Copyright ©The Author(s) 2023.
World J Clin Cases. Jun 6, 2023; 11(16): 3714-3724
Published online Jun 6, 2023. doi: 10.12998/wjcc.v11.i16.3714
Table 1 Characteristics of various spasmolytic polypeptide-expressing metaplasia inducers
Inducers of SPEM
Pharmacological action
Inflammatory response
Dosage and usage
Time to onset of SPEM
DMP-777It may cause backwash of acid into the cell leading to parietal cell deathNo significant inflammatory response in reaction the acute parietal cell loss> 200 mg/kg/d, oral gavage7–10 d(1) SPEM induced by these drugs may completely revert to normal mucosal cell lineages after a withdrawal period, despite the profound oxyntic atrophy and SPEM; and (2) L-635 and tamoxifen elicit parietal cell loss and induce SPEM faster than DMP-777, because of the inflammation cause by L-635 and tamoxifen
L-635Same as DMP-777A prominent submucosal and intramucosal inflammatory infiltrate is observed350 mg/kg/d, oral gavage3 d
TamoxifenSame as DMP-777Inflammatory is scant than L-635≥ 3 mg/20 g body weight dose, oral or intra-peritoneal3 d
Table 2 The influence of the absence of additional signals and epidermal growth factor
AR-null mouseYesYesYes
TGF-α-null mouseNoNoNo
IL33 KO mouse + L635NoNoNo
ST2 KO mouse + L635NoNoNo
IL13 KO mouse + L635NoNoNo
IFN-γ overexpression mouseYesNoNo